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Abstract
Background: In spite of its establishment from the peripheral blood of a case with acute myeloid leukemia (AML)-
M1, HPB-AML-I shows plastic adherence with spindle-like morphology. In addition, lipid droplets can be induced in
HPB-AML-I cells by methylisobutylxanthine, hydrocortisone, and indomethacin. These findings suggest that HPB-
AML-I is similar to mesenchymal stem cells (MSCs) or mesenchymal stromal cells rather than to hematopoietic cells.
Methods: To examine this possibility, we characterized HPB-AML-I by performing cytochemical, cytogenetic, and
phenotypic analyses, induction of differentiation toward mesenchymal lineage cells, and mixed lymphocyte culture
analysis.
Results: HPB-AML-I proved to be negative for myeloperoxidase, while surface antigen analysis disclosed that it was
positive for MSC-related antigens, such as CD29, CD44, CD55, CD59, and CD73, but not for CD14, CD19, CD34,
CD45, CD90, CD105, CD117, and HLA-DR. Karyotypic analysis showed the presence of complicated abnormalities,
but no reciprocal translocations typically detected in AML cases. Following the induction of differentiation toward
adipocytes, chondrocytes, and osteocytes, HPB-AML-I cells showed, in conjunction with extracellular matrix
formation, lipid accumulation, proteoglycan synthesis, and alkaline phosphatase expression. Mixed lymphocyte
culture demonstrated that CD3
+ T-cell proliferation was suppressed in the presence of HPB-AML-I cells.
Conclusions: We conclude that HPB-AML-I cells appear to be unique neoplastic cells, which may be derived from
MSCs, but are not hematopoietic progenitor cells.
Background
Mesenchymal stem cells (MSCs) constitute a cell popula-
tion, which features self-renewal and differentiation into
adipocytes, chondrocytes, and osteocytes. Human MSCs
have been isolated from various tissues and organs, such
as muscle, cartilage, synovium, dental pulp, bone marrow,
tonsils, adipose tissues, placenta, umbilical cord, and thy-
mus (reviewed by [1]). The biological roles of MSCs were
initially described by Friedenstein and colleagues in
1970s. They observed bone formation and reconstitution
of the hematopoietic microenvironment in rodents with
subcutaneously transplanted MSCs (reviewed by [2]). In
addition to providing support for the early stage of hema-
topoiesis, MSCs have also been reported to suppress the
proliferation of CD3
+ T-cells [3], which led to the utiliza-
tion of MSCs in the management of various pathologic
conditions, such as graft-versus-host disease (GvHD)
after allogeneic bone marrow transplantation (reviewed
by [4-6]). Recent studies have successfully isolated can-
cer-initiating cells with properties similar to those of
MSCs from cases with some neoplasms, such as osteosar-
coma [7], Ewing’s sarcoma [8], and chondrosarcoma [9].
Furthermore, the characteristics of MSCs isolated from
cases with hematopoietic neoplasms have also been
investigated. Shalapour et al. [10] and Menendez et al.
[11] identified the presence of oncogenic fusion tran-
scripts, such as TEL-AML1, E2A-PBX1,a n dMLL rear-
rangements, in MSCs isolated from cases with B-lineage
acute lymphoblastic leukemia (B-ALL). These reports
suggested that some leukemias may be derived from the
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HPB-AML-I has been considered a unique cell line. In
spite of its establishment from the peripheral blood
mononuclear cells (PBMCs) of a case with acute mye-
loid leukemia (AML)-M1, this cell line reportedly has
the features of spindle-like morphology and plastic
adherence [12]. The detached HPB-AML-I cells were
surprisingly capable of proliferating and adhering to
plastic surfaces after passage. Immunophenotypic analy-
sis of HPB-AML-I demonstrated the absence of hemato-
poietic cell-surface antigens and showed that this cell
line resembles marrow stromal cells [12]. Moreover, in
the presence of methylisobutylxanthine, hydrocortisone,
and indomethacin, but not troglitazone, an increase in
the number of lipid droplets was observed in these cells
[12]. In view of these features, we further investigated
the possibility of HPB-AML-I being a neoplasm of MSC
origin.
Recently, some human MSC lines have been estab-
lished from the bone marrow [13,14] and umbilical cord
blood [15] cells of healthy donors. To establish a stable
cell line, genes encoding the human telomerase reverse
transcriptase (hTERT), bmi-1, E6, and E7 proteins were
transduced to prolong the life span of the healthy
donor-originated MSCs [13-15]. However, there have
been no reports of the establishment of MSC lines from
human bone marrow cells without in vitro gene trans-
duction. Since a number of the characteristics of HPB-
AML-I are not typically observed in leukemic cells, we
wondered whether HPB-AML-I cells are neoplastic cells
originating from the non-hematopoietic compartments
of bone marrow, such as MSCs.
Methods
Cell lines and cell culture
HPB-AML-I cells were kindly provided by Dr. K. Mori-
kawa (Sagami Women’s University, Sagamihara, Japan)
and 5 × 10
5 of these cells were cultured in 10 ml of
RPMI-1640 medium supplemented with L-glutamine
(Gibco, Carlsbad, CA), 10% fetal bovine serum (FBS)
(Clontech, Mountain View, CA), 50 U/ml of penicillin
(Lonza, Walkersville, MD), and 50 μg/ml of streptomy-
cin (Lonza). Cell culture was performed in a T-25 flask
and was maintained in a 37°C incubator humidified with
5% CO2. Cell passage was performed twice a week.
UCBTERT-21, the hTERT-transduced umbilical cord
blood mesenchymal stem cell (MSC) line [15], was
obtained from the Japanese Collection of Research Bior-
esources (JCRB, Osaka, Japan) and propagated in a T-75
flask in a total number of 1.5 × 10
5 cells. Cell culture
was maintained in 15 ml of Plusoid-M medium (Med
Shirotori, Tokyo, Japan) containing 5 μg/ml of gentami-
cin (Gibco). The culture medium was replaced twice a
week and cell passage was performed when the cultured
cells reached 80-90% of confluence.
Cytochemical analysis
The following cytochemical staining was performed
according to the manufacturer’s instructions: May Grün-
wald-Giemsa (Sysmex, Kobe, Japan), myeloperoxidase-
Giemsa, toluidine blue, alkaline phosphatase-Safranin O
(Muto, Tokyo, Japan), Sudan Black B-hematoxylin, oil
red O-hematoxylin (Sigma-Aldrich, St. Louis, MO), and
von Kossa-nuclear fast red (Diagnostic BioSystems, Plea-
santon, CA).
Cytogenetic analysis
Cytogenetic analysis was performed according to the
standard protocols. The karyotype was determined by
G-banding using trypsin and Giemsa (GTG) [16] to
examine 50 cells. The best metaphase was then photo-
graphed to determine the karyotype. The specimen was
also submitted to spectral karyotyping (SKY)-fluores-
cence in situ hybridization (FISH) assay according to
Ried’s method using whole chromosome painting
(WCP) libraries (cytocell for WCP) and a-satellite DNA
probes [17].
Cell-surface antigen analysis
Flow cytometric analysis was performed by using the fol-
lowing monoclonal antibodies recommended by the
International Society for Cellular Therapy (ISCT)
(reviewed by [2]) and monoclonal antibodies used in the
study of Wang et al. [18]: MP9 (CD14), SJ25C1 (CD19),
MAR4 (CD29), 8G12 (CD34), 515 (CD44), 2D1 (CD45),
IA10 (CD55), p282 (CD59), AD2 (CD73), 5E10 (CD90),
SN6 (CD105), 104D2 (CD117), and L243 (HLA-DR). All
of these monoclonal antibodies were obtained from BD
Biosciences (San Jose, CA), except for SN6 from Invitro-
gen (Carlsbad, CA). Cells were resuspended in a total
number of 2 × 10
5 in 50 μl of phosphate-buffered saline
(PBS) supplemented with 4% FBS, then incubated with
20 μl of monoclonal antibodies, except for 5E10 (2 μl)
and SN6 (5 μl ) ,f o r4 5m i na t4 ° C ,a n dt h ec o n j u g a t e d
cells fixed with 1 ml of 4% paraformaldehyde solution
(Wako, Osaka, Japan). Flow cytometric analysis was per-
formed with Cell Quest software and the FACSCalibur
device (BD Biosciences) to examine 20,000 events.
In vitro differentiation toward adipocytes, chondrocytes,
and osteocytes
To induce adipogenesis and osteogenesis, 1 × 10
3 cells
were cultured in 500 μl of medium in a four-well cham-
ber slide. Three days after propagation, the culture med-
ium was replaced with 500 μl of StemPro adipogenesis
or osteogenesis differentiation medium (Gibco) contain-
ing 5 μg/ml of gentamicin. Chondrogenesis was induced
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10
2 of the cells were resuspended in 10 μlo fc u l t u r e
medium and applied to the center of a culture well. A
96-well culture plate was used in our study. Two hours
after propagation, 100 μl of StemPro chondrogenesis dif-
ferentiation medium containing 5 μg/ml of gentamicin
was added. The differentiation medium was replaced
twice a week.
Mixed lymphocyte culture assay
PBMCs were separated from the heparinized peripheral
blood of a healthy donor by means of Ficoll-Paque den-
sity gradient centrifugation (Amersham Biosciences,
Uppsala, Sweden). CD3
+ T-cells were purified from
PBMCs by magnetic-activated cell sorting (MACS) posi-
tive selection (Miltenyi Biotec, Auburn, CA) and 1 × 10
6
of these cells were cultured for 48 h in a 96-well culture
plate in the presence of 12.5 μg/ml of phytohemaggluti-
nin (Wako) with or without irradiated (25 Gy) HPB-
AML-I and UCBTERT-21 (0, 1 × 10
3,1×1 0
4,a n d1×
10
5 cells/well) cells. From each culture well, 100 μlo f
cell suspension was pulsed with 10 μlo fC e l lC o u n t i n g
Kit-8 solution (Dojindo, Tokyo, Japan) at 37°C for 4 h.
The optical density at 450 nm was measured to deter-
mine cell viability in each of the culture wells.
Results
HPB-AML-I shows plastic adherence, negative
myeloperoxidase expression, and complex chromosomal
abnormalities
Inverted microscopic examination (Figure 1A) and
May Grünwald-Giemsa staining (Figure 1B) of HPB-
AML-I cells revealed that this cell line is composed of
round-polygonal and spindle-like cells. Unlike the
round-polygonal cells, HPB-AML-I cells with the spin-
dle-like morphology attached to plastic surfaces. Since
HPB-AML-I was established from a case with AML,
we examined this cell line for the presence of myelo-
peroxidase expression. The human acute promyelocytic
leukemia (APL) NB4 cell line was used as positive con-
trol in this examination (Figure 1C). We found that
HPB-AML-I was negative for myeloperoxidase expres-
sion (Figure 1D).
HPB-AML-I was also subjected to cytogenetic analysis,
which demonstrated the presence of a complex karyo-
type with a modal chromosome number of 64 (range:
57-65; Figure 2A). A single X chromosome and a num-
ber of other abnormalities, mainly consisting of chromo-
some gains, chromosome losses, translocations, and
deletions, were detected by SKY-FISH assay (Figure 2B).
There were no reciprocal chromosomal translocations,
which are frequently observed in AML cases.
HPB-AML-I expresses cell-surface antigens characteristic
for MSCs
HPB-AML-I was examined by means of flow cytometric
analysis for cell-surface antigens, which are widely used
to identify the presence of MSCs. HPB-AML-I expressed
CD29, CD44, CD55, CD59, and CD73, but no cell-sur-
face expression of CD14, CD19, CD34, CD90, CD105,
CD117, or HLA-DR was detected (Figure 3A). The cell-
surface antigen expression patterns of UCBTERT-21
[15] and F6 [21] cell lines and human MSCs isolated
from aorta-gonad-mesonephros, yolk sac [18], bone
marrow [22], and umbilical cord blood [23] are pre-
sented in Table 1 for comparison, showing that there
are phenotypic similarities between HPB-AML-I and
UCBTERT-21, which was established from human
umbilical cord blood and transduced with hTERT.
Flow cytometric analysis showed that 11.9% of HPB-
AML-I cells expressed CD45 (Figure 3A). We postulated
that the presence of two morphological phases of HPB-
AML-I cell line may be related to CD45 expression. For
addressing this hypothesis, we performed a prolonged
cell culture to increase the confluence, resulting in a
morphological change of spindle-like HPB-AML-I cells
toward round-polygonal. The round-polygonal cells,
A
NB4 HPB-AML-I
C D
B
Figure 1 Morphological and cytochemical characteristics of
HPB-AML-I. Inverted microscopic examination (A) and May
Grünwald-Giemsa staining (B) revealed that HPB-AML-I features a
round-polygonal (arrow) and spindle-like (arrowhead) morphology.
The human acute promyelocytic leukemia (APL) NB4 cell line was
used as positive control for myeloperoxidase staining. Positive
reactions are indicated with an arrow (C). Absence of
myeloperoxidase expression was observed in the cytospin-prepared
HPB-AML-I cells (D). Original magnification ×400.
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gently washing, but no trypsinization, were positive for
CD45 in 25.7% of cells (Figure 3B). Interestingly, the
CD45 expression returned to low positivity (10.1%) after
the round-polygonal cells were cultivated for another
three days, when they became adherent and spindle-like
(Figure 3B).
HPB-AML-I cells are capable of acquiring the properties of
adipocytes, chondrocytes, and osteocytes
To investigate the multipotency of HPB-AML-I cells, we
induced them to differentiate toward adipocytes, chon-
drocytes, and osteocytes. For comparison, the results of
examination of undifferentiated HPB-AML-I cells with
an inverted microscope are also shown (Figure 4A).
Two weeks after the induction of adipogenesis, morpho-
logical changes were observed in HPB-AML-I cells. The
differentiated cells retained the spindle-like morphology
or appeared as large polygonal cells. In addition, cyto-
plasmic vacuoles of various sizes were observed and
inverted microscopic examination showed that these
vacuoles occurred in solitary or aggregated formations
(Figure 4B). While Sudan Black B and oil red O did not
stain the cytoplasm of undifferentiated cells (Figure 4C
and 4E), the cytoplasmic vacuoles of differentiated HPB-
AML-I cells were positive for these cytochemical stain-
ing (Figure 4D and 4F), suggesting the presence of lipid
accumulation in the adipogenic-differentiated HPB-
AML-I cells.
Two weeks after the induction of chondrogenesis,
the differentiated HPB-AML-I cells showed polygonal
morphology, which made them distinct from the undif-
ferentiated cells. Inverted microscopic examination
demonstrated the presence of a number of vacuoles
in the cytoplasm of differentiated HPB-AML-I
cells (Figure 4G). In contrast to the undifferentiated
cells (Figure 4H), the differentiated HPB-AML-I cells
formed lacunae. The proteoglycan-rich extracellular
matrix, as indicated by positive toluidine blue staining,
surrounded the lacunae (Figure 4I). The presence of
lacunae, as well as extracellular proteoglycan accumu-
lation, suggested that the micromass of chondrogenic-
differentiated HPB-AML-I cells acquires the properties
of a cartilage.
Inverted microscopic examination three weeks after the
induction of osteogenesis demonstrated the presence of a
number of cell processes and an eccentrically located
nucleus in the differentiated HPB-AML-I cells (Figure
4J). The undifferentiated cells did not express alkaline
phosphatase as shown by negative cytochemical staining
for this protein (Figure 4K). On the other hand, cyto-
chemical staining resulted in positive staining for alkaline
phosphatase in the cytoplasm of differentiated HPB-
AML-I cells (Figure 4L). Moreover, the differentiated
Chromosome numbers 57 58 59 60 61 62 63 64 65 Total
Cell numbers 1 1 2 3 7 4 9 14 9 50
A
B
Figure 2 Cytogenetic features of HPB-AML-I. Karyotypic analysis performed on 50 HPB-AML-I cells demonstrated that each of these cells had
abnormal chromosome numbers ranging from 57 to 65 (modal: 64) (A). Reverse DAP (left side) and SKY-FISH (right side) of a representative
HPB-AML-I cell with a total number of 64 chromosomes are shown. The complete karyotype has been reported as: 61-65 <3n>, X, -X, -Y, der(X) t
(X;2)(p22.1;?), der(1;18)(q10;q10), der(1;22)(q10;q10), der(2) (2pter®2q11.2::2?::1p21®1pter), +der(3) t(3;14)(p13;q?), der(4) t(4;8)(q11;q11.2), der(5) t
(5;18)(p13;p11.2), i(5)(p10), -6, +der(7) t(3;7)(?;q11.2), +der(7) t(7;19)(q22;q13.1), -8, der(8) del(8)(p?) del(8)(q?), der(8) (qter®q22::p23®qter), -9, +10,
der(10;20)(q10;q10)x2, der(11) t(1;11)(?;q13), der(12) t(12;19)(p13;q13.1), +der(12) (5qter®5q13::12?::cen::12?::1?), +der(12) (5qter®5q13::12?::
cen::12?::1?::3?), -13, der(13) (13qter®13p11.2::11?::13?::11?), der(13) (13qter®13p11.2::11?::20?::11?::22?), -14, der(14) (14pter®14q24::3?::1?), der(15)
(15?::p11.2®q13::q15®qter), der(15) (15qter®15p11.2::7?::X?), -16, der(17) t(1;17)(p13;p11.2), der(17) t(9;17)(?;p11.2), der(18) t(18;?)(q11.2;?), -19, der
(19) t(5;19)(?;q11), +20, +20, +der(20) t(17;20)(?;p11.2), -21, -22, -22, +der(?) t(?;12)(q;15) (B).
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tes the extracellular matrix of the bone, as shown by
von Kossa staining (Figure 4M and 4N). These two find-
ings suggested the acquisition of osteogenic characteris-
tics by HPB-AML-I cells following the induction of
osteogenesis.
Inhibition of CD3
+ T-cell proliferation in the presence of
HPB-AML-I cells
CD3
+ T-cells obtained from peripheral blood were cul-
tured with or without HPB-AML-I cells. The XTT
absorbance levels at 450 nm, which show the viability of
CD3
+ T-cells, decreased in a dose-dependent manner
CD14 CD19 CD29 CD34
CD44 CD45 CD55 CD59
CD73 CD90 CD105 CD117
HLA-DR
E
v
e
n
t
s
A
CD45
Round-polygonal cells
CD45
Three days after propagation
B
Figure 3 Phenotypic profiles of HPB-AML-I. The expression of MSC-related antigens in the HPB-AML-I cell line is shown (A). CD45 expression
of round-polygonal HPB-AML-I cells (upper) and of the cells, which were cultivated for three days after propagation of round-polygonal HPB-
AML-I cells (lower), are shown (B). Flow cytometric results for the antigens indicated are shown in black. IgG  isotype (not shaded) was used as
negative control.
Table 1 Cell-surface antigen expression in HPB-AML-I and other MSCs
Antigens HPB-AML-I UCBTERT-21 [15] F6 [21] ISCT criteria [2] Wang et al. [18] Lee et al. [22] Majore et al. [23]
CD14 - - - - - - ND
CD19 - ND ND - - ND ND
CD29 + + + ND + ND ND
CD34 - - - - - ND ND
CD44 + + + ND + + +
CD45 - - - - - ND ND
CD55 + + ND ND ND ND ND
CD59 + + ND ND ND ND ND
CD73 + ND ND + + ND +
CD90 - - ND + ND + +
CD105 - ND ND + + + +
CD117 - - ND ND ND ND ND
HLA-DR - ND - - - ND ND
ND: not determined
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ings suggested that HPB-AML-I cells dose-dependently
suppress the antigen-driven proliferation of CD3
+
T-cells, which is also characteristic of MSCs.
Discussion
Even though HPB-AML-I was established from the
PBMCs of an AML-M1 case [12], this cell line presents
distinctive morphological features from AML. In terms
of cell-surface antigen expression, multilineage differen-
tiation, and CD3
+ T-cell suppression, the characteristics
of HPB-AML-I were found to be similar to those of
MSCs. Our findings presented here suggest that HPB-
AML-I may be a neoplastic cell line with MSC proper-
ties. Few reports have dealt with the establishment of
human neoplastic MSC lines. A previous study estab-
lished F6, a human neoplastic MSC line, from embryo-
nic bone marrow MSCs. Transplantation of F6 cells into
Undifferentiated Undifferentiated Differentiated Differentiated
Inverted microscopy Cytochemical staining
Oil red O-Hematoxylin
Toluidine blue
Alkaline phosphatase-Safranin O
A B
H
J
G
K L
I
Von Kossa-Nuclear Fast Red
C D
Sudan Black B-Hematoxylin
E F
M N
Figure 4 Morphological and cytochemical changes in HPB-AML-I cells following the induction of differentiation toward mesenchymal
lineage cells. Undifferentiated HPB-AML-I cells observed with an inverted microscope are shown for comparison (A). A representative HPB-AML-I
cell induced to differentiate toward adipocyte and showing spindle-like morphology and cytoplasmic vacuoles is indicated with an arrow (B).
Undifferentiated (C, E) and differentiated (D, F) HPB-AML-I cells were stained with Sudan Black B (C, D) and oil red O (E, F). The nucleus was
counterstained with hematoxylin. Positive Sudan Black B and oil red O staining of cytoplasmic vacuoles of the differentiated HPB-AML-I cells is
indicated with an arrow. Following the induction of differentiation toward chondrocytes, HPB-AML-I cells showed polygonal morphology with a
number of cytoplasmic vacuoles (arrow) (G). The micromass of undifferentiated (H) and differentiated (I) HPB-AML-I cells were stained with
toluidine blue. The presence of lacunae (arrows) and the toluidine blue-positive extracellular matrix (arrowheads) characteristic for a cartilage
were observed following the induction of chondrogenesis. The osteogenic-differentiated HPB-AML-I cells demonstrated a number of cell
processes (arrow) and an eccentrically located nucleus (arrowhead) (J). Undifferentiated (K) and differentiated (L) HPB-AML-I cells were
cytochemically examined for alkaline phosphatase expression. The nucleus was counterstained with Safranin O. Positive reactions are shown in
the differentiated HPB-AML-I cells with an arrow. Undifferentiated (M) and differentiated (N) HPB-AML-I cells were stained with von Kossa
method. The nucleus was counterstained with nuclear fast red. The extracellular depositions of calcium following the induction of osteogenesis
are indicated with an arrow. Original magnification x400; Size bar: 20 μm.
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and tissue metastasis [21,24]. To the best of our knowl-
edge, however, HPB-AML-I is the first neoplastic MSC
line derived from a leukemic case.
The appearance of HPB-AML-I cells in suspension
phase with their round-polygonal morphology intrigued
us. We observed that an increase in the population of
HPB-AML-I cells with such morphological patterns
occurs in conjunction with the increased confluence of
cultured cells. Morphological changes during culturing
have previously been described in the case of bone mar-
row MSCs. Choi et al. [25] reported that the morphol-
ogy of bone marrow MSCs changed from small spindle-
like in the first passage to large polygonal in the
later passages. In contrast to many other adherent cell
lines, HPB-AML-I cells with their round-polygonal mor-
phology were viable and capable of proliferating and
adhering to plastic surfaces following cell passage. Simi-
lar findings have been reported for the F6 cell line [21].
While the exact mechanisms remain to be elucidated,
we speculate that the loss of adherent capacity after
confluent condition may be a pivotal property to neo-
plasms originated from mesenchymal stem cells.
Flow cytometric analysis of HPB-AML-I disclosed that,
based on ISCT criteria, the cell-surface antigen expres-
sion patterns of this cell line were similar to those of
human MSCs (reviewed by [2]) with positive CD73 and
negative CD14, CD19, CD34, CD45 and HLA-DR expres-
sion. However, contrary to those criteria (reviewed by
[2]), HPB-AML-I did not express CD90 and CD105.
Absence of CD90 expression has also been observed in
UCBTERT-21 [15] and in human MSCs obtained from
umbilical cord blood [15,26]. MSCs lacking CD105
expression have been reported by Jiang et al. [27] and
Ishimura et al. [28], who isolated MSCs from the subcu-
taneous adipose tissue, and by Lopez-Villar et al. [29],
who extracted MSCs from the bone marrow of a myelo-
dysplastic syndrome case. These reports suggested that
the absence of CD90 and CD105 expression in HPB-
AML-I does not necessarily exclude the possibility that
this cell line is derived from MSCs. The differentiation
capability of MSCs with a negative CD105 expression has
been investigated by Jiang et al. [27] and Ishimura et al.
[28]. They found that this population of MSCs, while
showing adipogenic differentiation, lacked chondrogenic
and osteogenic differentiation. It is interesting that HPB-
AML-I could differentiate into three lineages despite of
CD105 negativity. In addition, a subpopulation of HPB-
AML-I expressed CD45, even though most of HPB-
AML-I cells were negative for CD45. Generally, CD45 is
negative in MSCs, but CD45 expression has been
detected in bone marrow MSCs from cases with multiple
myeloma [30,31]. It is therefore not surprising that neo-
plastic MSC line, such as HPB-AML-I, shows the aber-
rant expression of this antigen. Interestingly, CD45
expression in HPB-AML-I cells is likely to be transient,
as the expression levels of CD45 increased in round-poly-
gonal cells in the confluent cell culture and they
decreased after passage of round-polygonal cells. Normal
c e l l sa r ek n o w nt oh a v et h ep r o p e r t yo fc o n t a c ti n h i b i -
tion, which is lost in transformed cells. Therefore, cell-
to-cell contact might induce the aberrant expression of
CD45 with an unknown reason in HPB-AML-I cells.
By using inverted microscopic examination and cyto-
chemical staining, we demonstrated that HPB-AML-I
cells are able to acquire the properties of adipocytes,
chondrocytes, and osteocytes. The capability of MSCs to
differentiate toward mesenchymal lineage cells report-
edly correlates with their morphological and cell-surface
antigen expression patterns. Chang et al. [26] demon-
strated that MSCs isolated from human umbilical cord
blood consisted of cells with a flattened or spindle-like
morphology and that the capability of differentiating
toward adipocytes of the spindle-like MSCs was superior
than that of the flattened cells. Since such heteroge-
neous morphology is shared by HPB-AML-I, further
analyses are needed to characterize the difference
between the round-polygonal and spindle-like cells.
As also reported by previous studies of the immunomo-
dulatory effects on MSCs [18,32], we demonstrated that
HPB-AML-I cells are capable of suppressing CD3
+ T-cell
proliferation. Similar studies have been performed on
MSCs isolated from cases with various hematopoietic neo-
plasms, such as ALL, Hodgkin’s disease, non-Hodgkin’s
lymphoma, myelodysplastic syndrome, AML [33], and
CD3+ T-cells
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Figure 5 Inhibition of CD3
+ T-cell proliferation in the presence
of HPB-AML-I cells. Mixed lymphocyte culture was performed in
the presence or absence of HPB-AML-I cells (white columns). For
control, similar experiments were performed with UCBTERT-21 cells
(black columns). Results are presented as the XTT absorbance levels
at 450 nm, which were normalized to those of the baseline
experiments (cell culture in the absence of HPB-AML-I or UCBTERT-
21 cells). Means and standard deviations of four independent
experiments are shown. *, P < 0.05; **, P < 0.01 compared to the
baseline results
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Page 7 of 9chronic myeloid leukemia (CML) [34]. In contrast to our
results, Zhi-Gang et al. reported that bone marrow MSCs
isolated from AML cases did not inhibit the proliferation
of CD3
+ T-cells [33]. These findings suggest that bone
marrow MSCs from cases with hematopoietic neoplasms
may or may not be capable of inhibiting CD3
+ T-cell pro-
liferation as a consequence of the secretion of humoral
factors by neoplastic cells or the direct interaction with
them. It is therefore very interesting that HPB-AML-I,
regardless of its HSC or MSC origin, maintains the cap-
ability of inhibiting T-cell proliferation even after neoplas-
tic transformation.
The cytogenetic analysis revealed the presence of
complex chromosomal abnormalities in HPB-AML-I,
a l t h o u g ht h e s ew e r en o tt h es a m ea st h ef r e q u e n t l y
observed chromosomal alterations in AML cases. While
it is not fully understood whether MSCs isolated from
leukemic cases carry the cytogenetic characteristics
common to leukemic cells, previous studies reported the
absence of t(9;22)(q34;q11) chromosomal translocation
or BCR-ABL rearrangement in bone marrow MSCs
obtained from cases with Philadelphia (Ph) chromo-
some-positive CML [35,36]. On the other hand, a recent
study demonstrated the presence of leukemic reciprocal
translocation and fusion gene expression in bone mar-
row MSCs of MLL-AF4-positive B-ALL cases [11]. How-
ever, monoclonal Ig gene rearrangements, uncontrolled
cell proliferation, diminished cell apoptosis, and cell-
cycle arrest characteristic of leukemic cells were not
observed in the bone marrow MSCs of those cases [11].
Unfortunately, we could not obtain the karyotype of the
original leukemic cells. Therefore, the complex karyo-
type in HPB-AML-I may not correspond to the cytoge-
netic status of the primary cells. It is possible that the
complex karyotype of HPB-AML-I may include the
additional genetic changes, which occurred in vitro dur-
ing and after the establishment of the cell line. Never-
theless, the MSC-like properties of HPB-AML-I, as
shown in this study, suggest the possibility that the first
genetic event might have occurred at the stage of MSC.
Conclusions
In summary, we were able to demonstrate that HPB-
AML-I has morphological, cytochemical, and phenotypic
features, as well as the capability of differentiating
toward mesenchymal lineage cells and of suppressing
CD3
+ T-cell proliferation, which are all characteristic of
MSCs. Our findings suggest that HPB-AML-I cells may
represent a unique neoplastic cell line derived from
b o n em a r r o wM S C s .W eb e l i e v et h a tt h i sc e l ll i n ew i l l
make an important contribution to a better understand-
ing of the neoplastic transformation of bone marrow-
derived constituents.
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